Q/C Technologies, Inc. (QCLS) stock
QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.33+0.01 (+4.05%)
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
Q/C Technologies EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Q/C Technologies's EPS for the twelve months ending Sep 30, 2025 was -$160.20. For fiscal 2025 it was -$8.66. The highest annual figure on record is -$8.66 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.66 | – |
| FY2024 | Dec 31, 2024 | -$1080.87 | – |
| FY2023 | Dec 31, 2023 | -$517.01 | – |
| FY2022 | Dec 31, 2022 | -$1138.78 | – |
| FY2020 | Dec 31, 2020 | -$241.53 | – |
| FY2019 | Dec 31, 2019 | -$615.95 | – |
| FY2018 | Dec 31, 2018 | -$2161.16 | – |
| FY2017 | Dec 31, 2017 | -$13727.92 | – |
| FY2016 | Dec 31, 2016 | -$10650.60 | – |
| FY2015 | Dec 31, 2015 | -$31602.60 | – |
| FY2014 | Dec 31, 2014 | -$11523.60 | – |
| FY2013 | Dec 31, 2013 | -$16761.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.79 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.19 | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.50 | – |
| Q2 FY2025 | Jun 30, 2025 | -$51.10 | -242.4% |
| Q1 FY2025 | Mar 31, 2025 | -$0.36 | – |
| Q4 FY2024 | Dec 31, 2024 | -$106.24 | – |
| Q1 FY2024 | Mar 31, 2024 | -$498.58 | – |
| Q3 FY2023 | Sep 30, 2023 | $35.89 | – |
| Q2 FY2023 | Jun 30, 2023 | -$312.34 | – |
| Q1 FY2023 | Mar 31, 2023 | -$116.40 | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.73 | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.73 | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.49 | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.30 | – |
| Q3 FY2021 | Sep 30, 2021 | -$317.05 | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.88 | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.49 | – |
| Q3 FY2020 | Sep 30, 2020 | -$90.21 | – |
| Q2 FY2020 | Jun 30, 2020 | -$66.93 | – |
| Q1 FY2020 | Mar 31, 2020 | -$308.46 | – |
| Q4 FY2019 | Dec 31, 2019 | -$165.70 | – |
| Q3 FY2019 | Sep 30, 2019 | -$149.38 | – |
| Q2 FY2019 | Jun 30, 2019 | -$142.59 | – |
| Q1 FY2019 | Mar 31, 2019 | -$164.90 | – |
| Q3 FY2018 | Sep 30, 2018 | -$567.45 | – |
| Q2 FY2018 | Jun 30, 2018 | -$392.85 | – |
| Q1 FY2018 | Mar 31, 2018 | -$458.32 | -143.8% |
| Q2 FY2017 | Jun 30, 2017 | -$1571.40 | – |
| Q1 FY2017 | Mar 31, 2017 | -$3317.40 | – |
| Q4 FY2016 | Dec 31, 2016 | -$3523.57 | – |
| Q3 FY2016 | Sep 30, 2016 | $1047.60 | – |
| Q2 FY2016 | Jun 30, 2016 | -$3317.40 | – |
| Q1 FY2016 | Mar 31, 2016 | -$4888.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?